These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31713607)

  • 21. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
    Diacon AH; Dawson R; von Groote-Bidlingmaier F; Symons G; Venter A; Donald PR; van Niekerk C; Everitt D; Hutchings J; Burger DA; Schall R; Mendel CM
    Am J Respir Crit Care Med; 2015 Apr; 191(8):943-53. PubMed ID: 25622149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.
    Deshpande D; Srivastava S; Nuermberger E; Pasipanodya JG; Swaminathan S; Gumbo T
    Clin Infect Dis; 2016 Nov; 63(suppl 3):S88-S94. PubMed ID: 27742639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development.
    Gumbo T; Srivastava S; Deshpande D; Pasipanodya JG; Berg A; Romero K; Hermann D; Hanna D
    J Antimicrob Chemother; 2023 Apr; 78(4):953-964. PubMed ID: 36794692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.
    De Groote MA; Gilliland JC; Wells CL; Brooks EJ; Woolhiser LK; Gruppo V; Peloquin CA; Orme IM; Lenaerts AJ
    Antimicrob Agents Chemother; 2011 Mar; 55(3):1237-47. PubMed ID: 21135176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pretomanid for tuberculosis: a systematic review.
    Gils T; Lynen L; de Jong BC; Van Deun A; Decroo T
    Clin Microbiol Infect; 2022 Jan; 28(1):31-42. PubMed ID: 34400340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.
    Ibrahim M; Truffot-Pernot C; Andries K; Jarlier V; Veziris N
    Am J Respir Crit Care Med; 2009 Sep; 180(6):553-7. PubMed ID: 19590024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PA-824 , moxifloxacin and pyrazinamide combination therapy for tuberculosis.
    Dawson R; Diacon A
    Expert Opin Investig Drugs; 2013 Jul; 22(7):927-32. PubMed ID: 23687915
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Triple combination dry powder formulation of pretomanid, moxifloxacin, and pyrazinamide for treatment of multidrug-resistant tuberculosis.
    Fan C; Eedara BB; Sinha S; Uddin MKM; Doyle C; Banu S; Das SC
    Int J Pharm; 2024 Apr; 654():123984. PubMed ID: 38461874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis.
    Andries K; Gevers T; Lounis N
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4540-4. PubMed ID: 20713662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improving treatment outcome assessment in a mouse tuberculosis model.
    Mourik BC; Svensson RJ; de Knegt GJ; Bax HI; Verbon A; Simonsson USH; de Steenwinkel JEM
    Sci Rep; 2018 Apr; 8(1):5714. PubMed ID: 29632372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis.
    Deshpande D; Srivastava S; Bendet P; Martin KR; Cirrincione KN; Lee PS; Pasipanodya JG; Dheda K; Gumbo T
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29180526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings.
    Sotgiu G; Tiberi S; Centis R; D'Ambrosio L; Fuentes Z; Zumla A; Migliori GB
    Int J Infect Dis; 2017 Mar; 56():190-193. PubMed ID: 27816662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.
    Pasipanodya JG; Nuermberger E; Romero K; Hanna D; Gumbo T
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S10-7. PubMed ID: 26224767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New drug combination for TB is tested in unique trial.
    Kmietowicz Z
    BMJ; 2012 Jul; 345():e5060. PubMed ID: 22833631
    [No Abstract]   [Full Text] [Related]  

  • 35. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity of Moxifloxacin against
    Louie A; Duncanson B; Myrick J; Maynard M; Nole J; Brown D; Schmidt S; Neely M; Scanga CA; Peloquin C; Drusano GL
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
    Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
    PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis.
    Kubendiran G; Paramasivan CN; Sulochana S; Mitchison DA
    J Chemother; 2006 Dec; 18(6):617-23. PubMed ID: 17267339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nouveau short-course therapy and morphism mapping for clinical pulmonary
    Srivastava S; Wang JY; Magombedze G; Chapagain M; Huang HL; Deshpande D; Heysell SK; Pasipanodya JG; Gumbo T
    Antimicrob Agents Chemother; 2023 May; 95(5):. PubMed ID: 33558291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
    de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
    Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.